Abbott Laboratories Company Profile (NYSE:ABT)

About Abbott Laboratories

Abbott Laboratories logoAbbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Nutrition Products segment includes the sales of a line of adult and pediatric nutritional products. The Diagnostic Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Exchange: NYSE
  • Symbol: ABT
  • CUSIP: 00282410
Key Metrics:
  • Previous Close: $45.46
  • 50 Day Moving Average: $42.49
  • 200 Day Moving Average: $41.08
  • 52-Week Range: $36.76 - $45.79
  • Trailing P/E Ratio: 48.11
  • Foreward P/E Ratio: 16.39
  • P/E Growth: 1.65
  • Market Cap: $77.90B
  • Outstanding Shares: 1,727,997,000
  • Beta: 0.97
  • Net Margins: 6.71%
  • Return on Equity: 15.74%
  • Return on Assets: 8.27%
  • Debt-to-Equity Ratio: 0.29%
  • Current Ratio: 1.56%
  • Quick Ratio: 1.25%
Additional Links:
Companies Related to Abbott Laboratories:

Analyst Ratings

Consensus Ratings for Abbott Laboratories (NYSE:ABT) (?)
Ratings Breakdown: 3 Hold Ratings, 15 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $48.17 (6.85% upside)

Analysts' Ratings History for Abbott Laboratories (NYSE:ABT)
DateFirmActionRatingPrice TargetDetails
3/1/2017RBC Capital MarketsBoost Price TargetOutperform$46.00 -> $50.00View Rating Details
3/1/2017Royal Bank of CanadaBoost Price TargetOutperform -> Outperform$46.00 -> $50.00View Rating Details
2/17/2017Jefferies Group LLCReiterated RatingBuy$51.00View Rating Details
9/19/2016Bank of America CorpReiterated RatingBuyView Rating Details
8/10/2016BTIG ResearchReiterated RatingBuy$45.00View Rating Details
8/9/2016Deutsche Bank AGReiterated RatingBuyView Rating Details
7/28/2016ArgusReiterated RatingBuy$55.00View Rating Details
7/21/2016Barclays PLCBoost Price TargetOverweight$48.00 -> $50.00View Rating Details
6/21/2016Edward JonesUpgradeHold -> BuyView Rating Details
6/8/2016Credit Suisse GroupReiterated RatingBuyView Rating Details
5/12/2016Wells Fargo & CoReiterated RatingBuyView Rating Details
5/2/2016BMO Capital MarketsReiterated RatingBuyView Rating Details
4/30/2016S&P Equity ResearchReiterated RatingHoldView Rating Details
4/30/2016GabelliReiterated RatingBuyView Rating Details
4/28/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralView Rating Details
4/21/2016Cowen and CompanyReiterated RatingNeutral -> Buy$44.00 -> $48.00View Rating Details
4/14/2016First GlobalDowngradeOutperform -> MarketperformView Rating Details
3/28/2016Stifel NicolausBoost Price TargetBuy$42.00 -> $47.00View Rating Details
3/28/2016Leerink SwannBoost Price TargetMarket Perform$37.00 -> $40.00View Rating Details
1/29/2016Raymond James Financial, Inc.Lower Price TargetOutperform$46.00 -> $42.00View Rating Details
1/29/2016Goldman Sachs Group IncLower Price TargetNeutral$44.00 -> $40.00View Rating Details
1/29/2016William BlairDowngradeOutperform -> Market PerformView Rating Details
1/4/2016Morgan StanleyDowngradeOverweight -> Equal Weight$50.00View Rating Details
5/27/2015Evercore Partners Inc.Initiated CoverageBuy$54.00View Rating Details
5/26/2015Evercore ISIInitiated CoverageBuy$54.00View Rating Details
4/23/2015J P Morgan Chase & CoBoost Price TargetNeutral$46.00 -> $48.00View Rating Details
(Data available from 3/1/2015 forward)


Earnings History for Abbott Laboratories (NYSE:ABT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/6/2017Q416$0.65$0.65$5.41 billion$5.33 billionViewListenView Earnings Details
10/19/2016Q316$0.58$0.59$5.29 billion$5.30 billionViewListenView Earnings Details
7/20/2016Q216$0.53$0.55$5.24 billion$5.30 billionViewListenView Earnings Details
4/20/2016Q116$0.39$0.41$4.77 billion$4.90 billionViewListenView Earnings Details
1/28/2016Q415$0.61$0.62$5.31 billion$5.20 billionViewListenView Earnings Details
10/21/2015Q315$0.53$0.54$5.16 billion$5.15 billionViewListenView Earnings Details
7/22/2015Q215$0.50$0.52$5.15 billion$5.20 billionViewListenView Earnings Details
4/22/2015Q115$0.42$0.47$4.85 billion$4.90 billionViewListenView Earnings Details
1/29/2015Q414$0.69$0.71$5.48 billion$5.36 billionViewListenView Earnings Details
10/22/2014Q314$0.59$0.62$5.62 billion$5.10 billionViewListenView Earnings Details
7/16/2014Q214$0.51$0.54$5.53 billion$5.55 billionViewListenView Earnings Details
4/16/2014Q114$0.36$0.41$5.29 billion$5.24 billionViewListenView Earnings Details
1/22/2014Q413$0.58$0.58$5.72 billion$5.66 billionViewListenView Earnings Details
10/16/2013Q313$0.52$0.55$5.46 billion$5.37 billionViewListenView Earnings Details
7/17/2013Q2 2013$0.44$0.46$5.53 billion$5.45 billionViewListenView Earnings Details
4/17/2013Q1 2013$0.41$0.42$5.42 billion$5.38 billionViewListenView Earnings Details
1/23/2013Q4 2012$1.50$1.51$10.58 billion$10.80 billionViewListenView Earnings Details
10/17/2012$1.28$1.30ViewN/AView Earnings Details
7/18/2012$1.22$1.23ViewN/AView Earnings Details
4/18/2012$1.00$1.03ViewN/AView Earnings Details
1/25/2012$1.44$1.45ViewN/AView Earnings Details
10/19/2011$1.17$1.18ViewN/AView Earnings Details
7/20/2011$1.12$1.12ViewN/AView Earnings Details
4/20/2011$0.90$0.91ViewN/AView Earnings Details
1/26/2011$1.29$1.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Abbott Laboratories (NYSE:ABT)
Current Year EPS Consensus Estimate: $2.45 EPS
Next Year EPS Consensus Estimate: $2.75 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.39$0.40$0.39
Q2 20165$0.51$0.54$0.53
Q3 20163$0.58$0.60$0.59
Q4 20163$0.63$0.67$0.65
Q1 20172$0.43$0.50$0.47
Q2 20172$0.60$0.62$0.61
Q3 20172$0.64$0.69$0.67
Q4 20172$0.68$0.74$0.71
Q1 20181$0.53$0.53$0.53
Q2 20181$0.69$0.69$0.69
Q3 20181$0.78$0.78$0.78
Q4 20181$0.85$0.85$0.85
(Data provided by Zacks Investment Research)


Current Dividend Information for Abbott Laboratories (NYSE:ABT)
Annual Dividend:$1.06
Dividend Yield:2.35%
Dividend Growth:22.90% (3 Year Average)
Payout Ratio:113.98% (Based on Trailing 12 Months of Earnings)
43.27% (Based on Current Year Consensus EPS Estimate)
38.55% (Based on Next Year Consensus EPS Estimate)
Track Record:44 Years of Consecutive Dividend Growth

Dividend History for Abbott Laboratories (NYSE:ABT)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Abbott Laboratories (NYSE:ABT)
Insider Ownership Percentage: 0.26%
Institutional Ownership Percentage: 62.20%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/23/2017Robert E FunckVPSell25,500$45.50$1,160,250.00View SEC Filing  
2/22/2017Roger BirdInsiderSell13,222$45.02$595,254.44View SEC Filing  
2/21/2017Deepak S NathInsiderSell319$44.98$14,348.62View SEC Filing  
1/31/2017Heather L MasonInsiderSell35,700$40.77$1,455,489.00View SEC Filing  
12/20/2016Brian J BlaserInsiderBuy15,580$38.45$599,051.00View SEC Filing  
12/14/2016Robert B FordInsiderBuy12,775$39.09$499,374.75View SEC Filing  
11/10/2016Miles D WhiteChairmanBuy121,456$40.45$4,912,895.20View SEC Filing  
11/1/2016Sally E BlountDirectorBuy5,100$39.24$200,124.00View SEC Filing  
9/26/2016Daniel Gesua Sive SalvadoriSVPSell815$41.71$33,993.65View SEC Filing  
7/28/2016Stephen R FussellInsiderSell41,500$45.00$1,867,500.00View SEC Filing  
7/26/2016Michael J WarmuthInsiderSell26,800$43.49$1,165,532.00View SEC Filing  
7/25/2016Miles D WhiteChairmanBuy242,547$43.18$10,473,179.46View SEC Filing  
7/25/2016Robert E FunckVPSell26,800$43.08$1,154,544.00View SEC Filing  
6/28/2016Hubert L AllenEVPSell3,400$37.14$126,276.00View SEC Filing  
6/15/2016Jared WatkinSVPSell552$37.63$20,771.76View SEC Filing  
6/1/2016Brian B YoorCFOSell565$39.49$22,311.85View SEC Filing  
4/28/2016Deepak S NathSVPSell53$41.31$2,189.43View SEC Filing  
3/31/2016Jaime ContrerasSVPSell462$41.78$19,302.36View SEC Filing  
2/29/2016Brian B YoorCFOSell865$39.12$33,838.80View SEC Filing  
2/29/2016Deepak S NathSVPSell793$39.27$31,141.11View SEC Filing  
2/29/2016Robert B FordEVPSell1,706$39.28$67,011.68View SEC Filing  
2/29/2016Robert E FunckVPSell1,333$39.30$52,386.90View SEC Filing  
2/22/2016Jared WatkinSVPSell554$39.09$21,655.86View SEC Filing  
2/16/2016Deepak S. NathSVPSell171$37.13$6,349.23View SEC Filing  
12/16/2015Miles D. WhiteCEOSell438,000$46.00$20,148,000.00View SEC Filing  
8/18/2015Stephen R. FussellEVPSell13,096$50.46$660,824.16View SEC Filing  
4/27/2015Heather L MasonEVPSell13,500$47.45$640,575.00View SEC Filing  
4/27/2015Roger BirdSVPSell28,548$47.57$1,358,028.36View SEC Filing  
3/26/2015J. Scott WhiteSVPSell12,483$46.68$582,706.44View SEC Filing  
3/2/2015Jaime ContrerasSVPSell9,209$47.34$435,954.06View SEC Filing  
2/4/2015John M CapekEVPSell34,292$45.66$1,565,772.72View SEC Filing  
11/25/2014Jaime ContrerasSVPSell51,600$44.07$2,274,012.00View SEC Filing  
10/29/2014Miles D WhiteCEOSell440,800$42.52$18,742,816.00View SEC Filing  
3/3/2014John LandgrafEVPSell17,293$39.38$680,998.34View SEC Filing  
3/3/2014Katherine DoyleSVPSell6,639$39.01$258,987.39View SEC Filing  
3/3/2014Robert FunckVPSell1,413$38.97$55,064.61View SEC Filing  
2/18/2014John LandgrafEVPSell1,583$39.10$61,895.30View SEC Filing  
1/29/2014Michael WarmuthEVPSell11,430$36.21$413,880.30View SEC Filing  
12/6/2013Jean-Yves PaveeSVPSell5,855$37.46$219,328.30View SEC Filing  
11/7/2013Stephen FussellEVPSell10,466$37.59$393,416.94View SEC Filing  
10/30/2013Jaime ContrerasSVPSell25,368$36.85$934,810.80View SEC Filing  
6/7/2013Heather L MasonSVPSell12,000$37.01$444,120.00View SEC Filing  
2/1/2013William A OsbornDirectorBuy10,000$33.86$338,600.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Abbott Laboratories (NYSE:ABT)
DateHeadline logoDiagnostic company Alere says to delay filing annual report (NYSE:ABT) - March 1 at 8:40 AM
News IconLonger Investments Inc. Boosts Position in Abbott Laboratories (ABT) (NYSE:ABT) - February 28 at 3:17 PM
News IconStock Price of Abbott Laboratories (ABT) Increases 2.22% (NYSE:ABT) - February 28 at 3:17 PM
News IconThe Abbott Laboratories (ABT) Shares Bought by JNBA Financial Advisors (NYSE:ABT) - February 28 at 3:17 PM
News IconInsider Trading at Abbott Laboratories? (NYSE:ABT) - February 28 at 3:17 PM
News IconStock Check: Viewing Levels for Abbott Laboratories (ABT) - Midway Monitor (NYSE:ABT) - February 27 at 3:25 PM
News IconWhat Analysts Report Shows About Abbott Laboratories (NYSE:ABT)? - Transcript Daily (NYSE:ABT) - February 27 at 5:15 AM logoAbbott Labs (ABT) Up 10.8% Since Earnings Report: Can It Continue? - Nasdaq (NYSE:ABT) - February 27 at 5:15 AM logoAbbott Labs (ABT) Up 10.8% Since Earnings Report: Can It Continue? (NYSE:ABT) - February 27 at 5:15 AM
News IconAbbott Laboratories (ABT) : Checking the Chart - The USA Commerce (NYSE:ABT) - February 25 at 3:15 PM logoInsider Trading Activity Abbott Laboratories (NYSE:ABT) – VP Sold 25,500 shares of Stock (NYSE:ABT) - February 25 at 1:19 AM
News IconDividend Stock Updates: Abbott Laboratories (ABT) (NYSE:ABT) - February 24 at 8:17 PM
News IconAverage Brokerage Rating Of Abbott Laboratories (ABT), Annaly Capital Management, Inc. (NLY) - The USA Commerce (NYSE:ABT) - February 24 at 3:16 PM logo(ABBV), Abbott Laboratories (NYSE:ABT) - 2 Dividend Aristocrats ... - Benzinga (NYSE:ABT) - February 24 at 9:31 AM
News IconWhat Abbott Laboratories (ABT) And Its Chart Reveal Today - NY Stock News (NYSE:ABT) - February 24 at 9:31 AM
News IconThe Charts For Abbott Laboratories (ABT) Is Speaking Volumes Today - NY Stock News (NYSE:ABT) - February 24 at 9:31 AM logoInsider Trading Activity Abbott Laboratories (NYSE:ABT) – Insider Sold 319 shares of Stock (NYSE:ABT) - February 23 at 8:18 PM
News IconAbbott Laboratories (NYSE:ABT) To Announce June 2016 Results (NYSE:ABT) - February 23 at 8:18 PM
News IconRelative Strength Index Reveals Abbott Laboratories (NYSE:ABT) Has Hit Overbought Range (NYSE:ABT) - February 23 at 8:18 PM
News IconIndicator Level Summary for Abbott Laboratories (ABT) - Baldwin Journal (NYSE:ABT) - February 23 at 3:17 PM
News IconForward Earnings Estimate of Abbott Laboratories(ABT) - Highland Mirror (NYSE:ABT) - February 23 at 3:17 PM logoABBOTT LABORATORIES Financials (NYSE:ABT) - February 23 at 3:17 PM logoFTC Settles Charges of Anti-Competition in Abbot, St. Jude Deal (NYSE:ABT) - February 23 at 3:17 PM logoInsider Trading Activity Abbott Laboratories (NYSE:ABT) – Insider Sold 13,222 shares of Stock (NYSE:ABT) - February 23 at 1:19 AM
News IconStock Price of Abbott Laboratories (ABT) Increases 4.56% (NYSE:ABT) - February 22 at 8:17 PM
News IconThe Abbott Laboratories (ABT) Plans $0.27 Quarterly Dividend (NYSE:ABT) - February 22 at 8:17 PM logoAbbott Laboratories Declares Quarterly Dividend (NYSE:ABT) - February 22 at 8:17 PM logoEU mergers and takeovers (Feb 22) (NYSE:ABT) - February 22 at 3:15 PM
News IconThe Technical Case for and Against Abbott Laboratories (ABT) - The USA Commerce (NYSE:ABT) - February 22 at 11:47 AM
News IconStock Overbuying Recap: Abbott Laboratories (NYSE:ABT) - Post Registrar (NYSE:ABT) - February 22 at 11:47 AM
News IconThe Technicals For Abbott Laboratories (ABT) Have Been Dissected (Brutally) - NY Stock News (NYSE:ABT) - February 21 at 3:32 PM logoABBOTT LABORATORIES Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Statements an (NYSE:ABT) - February 21 at 3:32 PM logoAbbott Commences Exchange Offers and Consent Solicitations for St. Jude Medical, LLC Notes (NYSE:ABT) - February 21 at 3:32 PM
News IconAverage Brokerage Rating Of Medtronic plc (MDT), Abbott Laboratories (ABT) - The USA Commerce (NYSE:ABT) - February 21 at 5:32 AM
News IconThe Case for and Against Abbott Laboratories (ABT) - StockNewsJournal (NYSE:ABT) - February 21 at 5:32 AM
News IconHow Does the Chart Look for Abbott Laboratories (ABT) ? - The USA Commerce (NYSE:ABT) - February 17 at 6:51 PM logoAnalyst Activity – Jefferies Group LLC Reiterates Buy on Abbott Laboratories (NYSE:ABT) - Market Exclusive (NYSE:ABT) - February 17 at 6:51 PM logoAbbott Declares 373rd Consecutive Quarterly Dividend (NYSE:ABT) - February 17 at 6:51 PM logoABBOTT LABORATORIES Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial St (NYSE:ABT) - February 17 at 6:51 PM logoAbbott Laboratories declares $0.265 dividend (NYSE:ABT) - February 17 at 11:38 AM logoHow diabetes data from Europe could help this East Bay company (NYSE:ABT) - February 16 at 8:17 PM
News IconComprehensive Stock Analysis of: Abbott Laboratories (NYSE:ABT) (NYSE:ABT) - February 16 at 8:17 PM
News IconAbbott Laboratories (NYSE:ABT) Stock Technicals Hit Strength (NYSE:ABT) - February 16 at 8:17 PM
News IconQuantitative Systematic Strategies LLC Has $1931000 Position in Abbott Laboratories (ABT) (NYSE:ABT) - February 16 at 8:17 PM
News IconWhat are Analyst's Indicators for Abbott Laboratories (ABT), The Dow Chemical Company (DOW) - The USA Commerce (NYSE:ABT) - February 16 at 3:17 PM
News IconChecking the Overall Picture for Abbott Laboratories (ABT) - StockNewsJournal (NYSE:ABT) - February 16 at 3:16 PM
News IconWhy to Keeping Eye on Wal-Mart Stores, Inc. (WMT), Abbott Laboratories (ABT)? - StockNewsJournal (NYSE:ABT) - February 16 at 5:59 AM logoReal-World Data from Abbott's FreeStyle® Libre Show Association Between Higher Frequency of Glucose Monitoring and Improved Glucose Control for People with Diabetes (NYSE:ABT) - February 16 at 5:59 AM
News IconWhat Analysts are Predicting For Abbott Laboratories (ABT), The Walt Disney Company (DIS)? - The USA Commerce (NYSE:ABT) - February 14 at 3:20 PM logoMakeover Complete, Abbott Is Ready To Rumble - Seeking Alpha (NYSE:ABT) - February 13 at 8:21 PM


What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Friday, February 17th. Investors of record on Friday, April 14th will be paid a dividend of $0.265 per share on Monday, May 15th. This represents a $1.06 dividend on an annualized basis and a yield of 2.35%. The ex-dividend date is Tuesday, April 11th.

Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2017?

18 brokerages have issued twelve-month price objectives for Abbott Laboratories' stock. Their forecasts range from $40.00 to $55.00. On average, they expect Abbott Laboratories' share price to reach $48.17 in the next year.

When will Abbott Laboratories announce their earnings?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, April, 18th 2017.

What are analysts saying about Abbott Laboratories stock?

Here are some recent quotes from research analysts about Abbott Laboratories stock:

  • According to Zacks Investment Research, "Abbott has been reshaping its portfolio through strategic acquisitions/divestitures for long-term growth. The St. Jude Medical buyout will complement its cardiovascular devices business. On the other hand,  in order to focus on key areas, cardiovascular devices and diagnostics, Abbott inked a deal to divest its vision care business, Medical Optics, to J&J. Abbott’s initiative to realign the EPD segment was a step in the right direction given the challenging market conditions faced by the division. Shares of Abbott has outperformed the Zacks classified Large cap pharmaceuticals industry in the last one month. The company recently filed a complaint to terminate its proposed acquisition of Alere, based on a substantial deterioration in the latter’s value following the merger agreement.  Also, weakness in the nutrition business in China and sluggish growth in the Venezuelan market is concerning." (1/11/2017)

  • Credit Suisse Group analysts commented, "We expect a fairly high level of physician interest in Absorb in straightforward lesions. Our Jan. survey of US cardiologists implied 11% Absorb unit share in year 1 post-launch, though, assuming approval, we expect Absorb to face reimbursement/coverage challenges if a meaningful price premium is established (until/unless longer- term data shows an outcomes benefit). We currently forecast 5% US Absorb unit share in 2017 of which ½ comes from Xience & ½ from BSX/MDT. Share price performance 36 41 46 51 Mar-15 Jun-15 Sep-15 Dec-15 Daily Mar 16, 2015 – Mar 11, 2016, 3/16/15 = US$47.83 Price Indexed S&P 500 INDEX On 03/11/16 the S&P 500 INDEX closed at 2022.19 Quarterly EPS Q1 Q2 Q3 Q4 2015A 0.47 0.52 0.55 0.62 2016E 0.39 0.54 0.58 0.66 2017E 0.44 0.61 0.65 0.74 Financial and valuation metrics Year 12/15A 12/16E 12/17E 12/18E EPS (CS adj.) (US$) 2.16 2.17 2.43 2.71 Prev. EPS (US$) — — — — P/E (x) 18.7 18.6 16.6 14.9 P/E rel." (3/15/2016)

Who owns Abbott Laboratories stock?

Abbott Laboratories' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (4.60%), FMR LLC (0.94%), Franklin Resources Inc. (0.60%), Institutional Capital LLC (0.51%), Dimensional Fund Advisors LP (0.46%) and Westwood Holdings Group Inc. (0.30%). Company insiders that own Abbott Laboratories stock include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, J Scott White, Jaime Contreras, Jared Watkin, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount and Stephen R Fussell.

Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?

Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Thrivent Financial for Lutherans, FMR LLC, AQR Capital Management LLC, Institutional Capital LLC, Franklin Resources Inc., Aberdeen Asset Management PLC UK and Orbimed Advisors LLC. Company insiders that have sold Abbott Laboratories stock in the last year include Brian B Yoor, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Michael J Warmuth, Robert E Funck, Roger Bird and Stephen R Fussell.

Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?

Abbott Laboratories' stock was purchased by a variety of institutional investors in the last quarter, including Westwood Holdings Group Inc., Dimensional Fund Advisors LP, Asset Management One Co. Ltd., Renaissance Technologies LLC, State Street Corp, Russell Investments Group Ltd., Loomis Sayles & Co. L P and DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount.

How do I buy Abbott Laboratories stock?

Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Abbott Laboratories stock cost?

One share of Abbott Laboratories stock can currently be purchased for approximately $45.08.

Abbott Laboratories (NYSE:ABT) Chart for Wednesday, March, 1, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Earnings History Chart

Earnings by Quarter for Abbott Laboratories (NYSE:ABT)

Dividend History Chart

Dividend Payments by Quarter for Abbott Laboratories (NYSE:ABT)

Last Updated on 3/1/2017 by Staff